Retinopathy of prematurity: a global perspective and recent developments
Retinopathy of prematurity (ROP) is a significant cause of potentially preventable blindness
in preterm infants worldwide. It is a disease caused by abnormal retinal vascularization that …
in preterm infants worldwide. It is a disease caused by abnormal retinal vascularization that …
Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)
ASH Tsai, HD Chou, XC Ling, T Al-Khaled… - Progress in retinal and …, 2022 - Elsevier
The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …
survival of very low birth weight infants in developed countries. This epidemic is also fueled …
2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study) …
N Marlow, A Stahl, D Lepore, A Fielder… - The Lancet Child & …, 2021 - thelancet.com
Background Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors is
increasingly used to treat retinopathy of prematurity (ROP) in the absence of evidence about …
increasingly used to treat retinopathy of prematurity (ROP) in the absence of evidence about …
[HTML][HTML] Retinopathy of prematurity: A review of pathophysiology and signaling pathways
M Fevereiro-Martins, C Marques-Neves… - survey of …, 2023 - Elsevier
Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the retina and a leading
cause of visual impairment and childhood blindness worldwide. The disease is …
cause of visual impairment and childhood blindness worldwide. The disease is …
Low-and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes
SF Freedman, A Hercinovic, DK Wallace, RT Kraker… - Ophthalmology, 2022 - Elsevier
Purpose Low-dose and very low-dose intravitreal bevacizumab (IVB) have been reported to
be successful in short-term treatment of type 1 retinopathy of prematurity (ROP), down to an …
be successful in short-term treatment of type 1 retinopathy of prematurity (ROP), down to an …
Inhibition of APE1/Ref-1 for neovascular eye diseases: From biology to therapy
GD Hartman, NA Lambert-Cheatham… - International Journal of …, 2021 - mdpi.com
Proliferative diabetic retinopathy (PDR), neovascular age-related macular degeneration
(nvAMD), retinopathy of prematurity (ROP) and other eye diseases are characterized by …
(nvAMD), retinopathy of prematurity (ROP) and other eye diseases are characterized by …
Vascular endothelial growth factor signaling in models of oxygen-induced retinopathy: insights into mechanisms of pathology in retinopathy of prematurity
A Ramshekar, ME Hartnett - Frontiers in Pediatrics, 2021 - frontiersin.org
Retinopathy of prematurity (ROP) is a leading cause of blindness in children worldwide.
Blindness can occur from retinal detachment caused by pathologic retinal angiogenesis into …
Blindness can occur from retinal detachment caused by pathologic retinal angiogenesis into …
Retinopathy of prematurity: from oxygen management to molecular manipulation
J Woods, S Biswas - Molecular and Cellular Pediatrics, 2023 - Springer
Introduction Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the
premature retina with the potential to progress to extraretinal neovascularisation. This review …
premature retina with the potential to progress to extraretinal neovascularisation. This review …
Plasma levels of bevacizumab and vascular endothelial growth factor after low-dose bevacizumab treatment for retinopathy of prematurity in infants
ME Hartnett, DK Wallace, TW Dean, Z Li… - JAMA …, 2022 - jamanetwork.com
Importance Intravitreal bevacizumab effectively treats severe retinopathy of prematurity
(ROP), but it enters the bloodstream and may reduce serum vascular endothelial growth …
(ROP), but it enters the bloodstream and may reduce serum vascular endothelial growth …
Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal Anti–Vascular endothelial growth factor
Purpose To compare rates of short-term retinal detachment (RD) of infants treated for type 1
retinopathy of prematurity (ROP) with intravitreal anti–vascular endothelial growth factor …
retinopathy of prematurity (ROP) with intravitreal anti–vascular endothelial growth factor …